All individual numbers are from the SEC provided Financial Statement and Notes Data Sets. No guarantee is made for their accuracy. This report only shows the values that are common to a significant number of companies.
AXOVANT GENE THERAPIES LTD.: Last Reported 3/31/2020

Business Address

11-12 ST. JAMES'S SQUARE
SUITE 1, 3RD FLOOR
LONDON, GB SW1Y 4LB

Mailing Address

11 TIMES SQUARE
33RD FLOOR
NEW YORK, NY US 10036
Phone Number: 44 203 318 9708 / State Incorporated: / Fiscal Year End 3/31

Balance Sheet

Date 3/31/2020 12/31/2019 9/30/2019 6/30/2019 4/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018 12/31/2017 9/30/2017 6/30/2017 3/31/2017
Cash and Cash Equivalents $80,752,000.00 $27,812,000.00 $60,255,000.00 $84,176,000.00 -- $106,999,000.00 -- $90,726,000.00 $92,934,000.00 $154,337,000.00 -- -- -- --
Accounts Receivable Net Current -- -- -- -- -- -- -- -- -- -- -- -- -- --
Inventory -- -- -- -- -- -- -- -- -- -- -- -- -- --
Prepaid Expenses and Other Current Assets $2,971,000.00 $3,621,000.00 $4,503,000.00 $5,657,000.00 -- $5,859,000.00 -- -- -- $2,174,000.00 -- -- -- --
Total Current Assets $85,430,000.00 $33,421,000.00 $66,829,000.00 $91,749,000.00 -- $114,584,000.00 -- -- -- $158,262,000.00 -- -- -- --
Property Plant and Equipement $801,000.00 $980,000.00 $1,081,000.00 $1,115,000.00 -- $1,278,000.00 -- -- -- $2,524,000.00 -- -- -- --
Intangible Assets Net -- -- -- -- -- -- -- -- -- -- -- -- -- --
Goodwill -- -- -- -- -- -- -- -- -- -- -- -- -- --
Other Assets $46,000.00 $46,000.00 $46,000.00 $46,000.00 -- $973,000.00 -- -- -- -- -- -- -- --
Total Assets $93,680,000.00 $42,264,000.00 $76,064,000.00 $101,445,000.00 -- $122,706,000.00 -- -- -- $160,786,000.00 -- -- -- --
Accounts Payable $4,412,000.00 $347,000.00 $1,567,000.00 $2,896,000.00 -- $1,698,000.00 -- -- -- $3,949,000.00 -- -- -- --
Accrued Liabilities $11,319,000.00 $20,334,000.00 $21,427,000.00 $27,698,000.00 -- $20,619,000.00 -- -- -- $31,862,000.00 -- -- -- --
Total Current Liabilities $32,122,000.00 $37,217,000.00 $59,024,000.00 $72,093,000.00 -- $66,493,000.00 -- -- -- $89,500,000.00 -- -- -- --
Long Term Debt $15,400,000.00 $15,303,000.00 $34,355,000.00 $39,400,000.00 -- $44,176,000.00 -- -- -- $52,678,000.00 -- -- -- --
Additional Paid-in Capital $820,257,000.00 $746,845,000.00 $744,506,000.00 $743,486,000.00 -- $741,318,000.00 -- -- -- $628,111,000.00 -- -- -- --
Accumulated Other Comprehensive Loss -- -- -- -- -- -- -- -- -- -- -- -- -- --
Accumulated Deficit $-758,644,000.00 $-741,996,000.00 $-727,957,000.00 $-714,100,000.00 -- $-686,016,000.00 -- -- -- $-556,951,000.00 -- -- -- --
Total Stockholders' Equity $61,558,000.00 $5,047,000.00 $17,040,000.00 $29,352,000.00 -- $56,213,000.00 $22,760,000.00 $19,879,000.00 $25,826,000.00 $71,286,000.00 -- -- -- $124,837,000.00
Controlling Interest in Subsidiaries -- -- -- -- -- -- -- -- -- -- -- -- -- --
Total Liabilities and Equity $93,680,000.00 $42,264,000.00 $76,064,000.00 $101,445,000.00 -- $122,706,000.00 -- -- -- $160,786,000.00 -- -- -- --

Statement of Operations

Date 3/31/2020 12/31/2019 9/30/2019 6/30/2019 4/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018 12/31/2017 9/30/2017 6/30/2017 3/31/2017
Total Revenues -- -- -- -- -- -- -- -- -- -- -- -- -- --
Cost of Revenues -- -- -- -- -- -- -- -- -- -- -- -- -- --
Gross Profit -- -- -- -- -- -- -- -- -- -- -- -- -- --
Research and Development $47,110,000.00 $8,267,000.00 $6,833,000.00 $21,090,000.00 -- $87,552,000.00 $21,483,000.00 $21,502,000.00 $37,418,000.00 $21,799,000.00 $37,346,000.00 $38,555,000.00 $43,712,000.00 --
Selling, General, and Administrative -- -- -- -- -- -- -- -- -- -- -- -- -- --
Total Operating Expenses $69,171,000.00 $53,118,000.00 $39,442,000.00 $27,558,000.00 -- $13,306,000.00 $32,416,000.00 $32,124,000.00 $49,172,000.00 $24,043,000.00 $55,378,000.00 $68,667,000.00 $65,230,000.00 --
Loss from Operations $-72,190,000.00 $-55,824,000.00 $-13,757,000.00 $-28,019,000.00 -- $-128,932,000.00 $-119,795,000.00 $-33,741,000.00 $-51,810,000.00 $-220,652,000.00 -- -- -- --
Loss Before Income Taxes $-72,190,000.00 -- -- -- -- $-128,932,000.00 -- -- -- $-220,652,000.00 -- -- -- --
Earnings Per Share Basic -- -- -- -- -- -- -- -- -- -- -- -- -- --
Weighted Average Shares Basic -- -- -- -- -- -- -- -- -- -- -- -- -- --
Earnings Per Share Diluted -- -- -- -- -- -- -- -- -- -- -- -- -- --
Weighted Average Shares Diluted -- -- -- -- -- -- -- -- -- -- -- -- -- --
Common Stock Shares Authorized 1,000,000,000 1,000,000,000 1,000,000,000 1,000,000,000 -- 1,000,000,000 -- -- -- 1,000,000,000 -- -- -- --
Common Stock Shares Outstanding 39,526,299 22,791,669 22,791,669 22,780,672 22,800,000 22,779,891 -- -- -- 13,473,512 -- -- -- --
Copyright 2020 PursePoor.com